Thymosin Alpha-1 vs LL-37

Evidence-based comparison · Updated 2026

Summary

Thymosin Alpha-1 is better suited for systemic immune modulation, T-cell support, and adjuvant use in chronic viral infections or cancer, backed by stronger clinical evidence (Grade B). LL-37 is more relevant for localized antimicrobial defense, wound healing, and innate immune activation, though it remains research-only (Grade C). Choose Thymosin Alpha-1 for adaptive immune concerns; consider LL-37 for antimicrobial or wound-healing applications.

Side-by-Side Comparison

	Thymosin Alpha-1	LL-37
Evidence	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data
Regulatory	CompoundableCompoundableLegal to compound in the US; approved in other jurisdictions or has historical approval	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits	+Immune system modulation and enhancement +Antiviral properties +Used in hepatitis B and C treatment +Cancer adjuvant therapy +Supports T-cell function	+Broad-spectrum antimicrobial effects +Modulates immune response +Promotes wound healing +Anti-inflammatory properties +May combat biofilms
Dosage	0.8-3.2 mg mg — 2-3x per week	5-10 mg mg — 2-3x weekly
Route	Subcutaneous	Subcutaneous, Intramuscular
Category	Immune & Inflammatory Modulation	Immune & Inflammatory Modulation

Full research page

Thymosin Alpha-1 →

Full research page

LL-37 →

Which Should You Choose?

Thymosin Alpha-1 operates primarily within the adaptive immune system, promoting T-cell maturation and antigen presentation, while LL-37 functions at the innate immune level, directly disrupting microbial membranes and recruiting inflammatory cells. Their mechanisms are complementary rather than overlapping.

Choose Thymosin Alpha-1 when:

+You are targeting T-cell deficiency or immune dysregulation in the context of chronic viral infections such as hepatitis B or C.
+You require an immunomodulatory agent with established clinical data and compoundable regulatory status for adjuvant cancer therapy or vaccine enhancement.
+Your goal is restoring systemic adaptive immune function rather than addressing localized infection or tissue repair.

Choose LL-37 when:

+You are researching localized or systemic antimicrobial activity against bacteria, fungi, or biofilm-forming organisms where direct membrane disruption is the desired mechanism.
+The research focus involves wound healing, tissue repair, or modulation of innate immune signaling at a cellular level.
+You are investigating bridging effects between innate and adaptive immunity in a controlled research setting where research-only status is acceptable.

Stacking Thymosin Alpha-1 with LL-37 is not a widely documented clinical protocol, but the combination is theoretically rational given their complementary roles in adaptive and innate immunity, and may be explored in research contexts targeting both systemic immune restoration and localized antimicrobial defense simultaneously.

Frequently Asked Questions

Do Thymosin Alpha-1 and LL-37 target the same immune pathways, or do they work on different arms of the immune system?⌄

They target distinct but interconnected immune pathways. Thymosin Alpha-1 primarily enhances the adaptive immune system by promoting T-cell maturation and activating dendritic cells for antigen presentation. LL-37, by contrast, acts on the innate immune system through direct antimicrobial membrane disruption and activation of pattern-recognition receptors such as FPRL1. Their combined use in research settings may offer broader immune coverage precisely because their mechanisms do not substantially overlap.

How do the evidence grades and regulatory statuses of these two peptides affect which one a researcher or clinician should prioritize?⌄

Thymosin Alpha-1 carries a Grade B evidence rating and is compoundable in several jurisdictions, meaning it has meaningful clinical trial data supporting its use in hepatitis and cancer adjuvant contexts. LL-37 holds a Grade C rating and is currently classified as research-only, indicating that human clinical evidence remains limited and it is not approved for therapeutic compounding. For any application requiring regulatory defensibility or clinical translation, Thymosin Alpha-1 is the more appropriate choice at this time.

If someone is dealing with a chronic viral infection that also involves secondary bacterial complications, would there be a rationale for using both peptides together?⌄

There is a theoretical rationale: Thymosin Alpha-1 could address the underlying adaptive immune deficit associated with chronic viral infection, while LL-37 could provide antimicrobial activity against secondary bacterial pathogens and support wound or tissue healing if tissue compromise is present. However, this combination has not been validated in controlled clinical trials, and LL-37 remains research-only, so dual use would be limited to research contexts with appropriate oversight.

Do these two peptides have meaningful differences in administration timeline or onset of effect?⌄

Thymosin Alpha-1 is typically administered subcutaneously on a schedule spanning weeks to months, reflecting its role in gradually restoring T-cell populations and immune homeostasis, with clinical endpoints often measured over multi-week intervals. LL-37 research protocols vary considerably given its earlier development stage, but its direct antimicrobial mechanism suggests a potentially faster local response compared to the slower systemic immunomodulatory arc of Thymosin Alpha-1. Meaningful side-by-side timeline comparisons in humans are not yet available in the published literature.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500 mots c vs semaglutide dsip vs melanotan ii retatrutide vs tirzepatide cjc 1295 vs ipamorelin